NewScen Coast Biotech

NewScen Coast Biotech, established in 2003, operates as a specialized manufacturer and supplier within the global in-vitro diagnostic sector. The company focuses on high-tech diagnostic reagent solutions, leveraging advanced microfluidics and colloidal gold rapid test technologies to provide precise clinical results. Their extensive product portfolio includes specialized test kits for infectious diseases, hormonal analysis, and cardiovascular conditions, alongside proprietary testing instruments designed for clinical efficiency. With over two decades of industry experience, the firm maintains rigorous compliance with international quality certifications, ensuring reliable performance for healthcare providers worldwide.

The organization maintains a robust operational footprint with 500-1,000 employees dedicated to research, development, and manufacturing excellence. By integrating sophisticated biotechnology with scalable production processes, NewScen Coast Biotech addresses critical diagnostic needs across diverse medical environments. The company's commitment to innovation is reflected in its specialized focus on rapid diagnostic reagents, which are essential for timely patient management and effective clinical decision-making in modern healthcare settings. Meet NewScen Coast Biotech's team to learn more about the leadership and technical expertise driving these diagnostic advancements.

Headquartered in Tianjin, China, the company leverages its strategic location to facilitate global distribution and supply chain management. As a key player in the pharmaceutical and healthcare industries, NewScen Coast Biotech continues to expand its market presence by delivering high-quality diagnostic tools that meet stringent global standards. Their focus on microfluidics and rapid testing remains central to their long-term growth strategy and commitment to improving diagnostic accessibility.